-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BC-005 in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BC-005 in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BC-005 in Asthma Drug Details:BC-005 is under development for the treatment of asthma. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HH-006 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HH-006 in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HH-006 in Hepatitis B Drug Details:HH-006 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QLS-101 in Open-Angle Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QLS-101 in Open-Angle Glaucoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.QLS-101 in Open-Angle Glaucoma Drug Details:QLS-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QLS-101 in Ocular Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QLS-101 in Ocular Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.QLS-101 in Ocular Hypertension Drug Details:QLS-101 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – QLS-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry QLS-101 Drug Details QLS-101 is under development for the treatment of ocular hypertension, normal...
-
Product Insights
Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glaucoma signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision, and reddening of the eye. The Glaucoma pipeline drugs market research report provides an analysis of the Glaucoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and...
-
Product Insights
Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Ocular Hypertension pipeline market research report provides an overview of the Ocular Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of...